Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Aug 30, 2026 → Dec 31, 2026
See other at-risk trials from Mayo Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 30, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Primary and study completion pushed from Apr 30, 2026 to Aug 30, 2026v5
  3. Primary and study completion dates: Dec 30, 2025 to Apr 30, 2026v4
  4. Primary and study completion dates: Sep 30, 2025 to Dec 30, 2025
    • Start date changed from estimate of Jul 2025 to Aug 1, 2025
    v3
  5. Start date: Jun 2025 to Jul 2025v2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,024 trials monitored
See 128 trials at risk
The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.
Trial Details
NCT Number NCT07006142
Lead Sponsor Mayo Clinic
Conditions
(from sponsor)		 Upper Endoscopy, GLP1-R-related Disease
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov